Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings

Marinus Pharmaceuticals (Nasdaq: MRNS) has announced that four abstracts regarding ganaxolone for seizure disorders have been accepted for poster presentations at medical meetings in October.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/11/2022 - 07:30 AM EDT

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that four abstracts have been accepted for poster presentation at upcoming medical meetings in October. Details are as follows:

51^st Child Neurology Society Annual Meeting: October 12-15; Cincinnati, Ohio

Poster #40: “Extended duration ganaxolone treatment for seizures associated with CDKL5 Deficiency Disorder: 1-year minimum open-label extension follow-up”

Date and time: Thursday, October 13 from 12:30-2:00 p.m. ET and 5:30-7:00 p.m. ET

Poster #62: “Effect of ganaxolone on behaviors in children with the CDKL5 Deficiency Disorder”

Date and time: Thursday, October 13 from 12:30-2:00 p.m. ET and 5:30-7:00 p.m. ET

Neocritical Care Society 20^th Annual Meeting: October 17-21; San Antonio, Texas

“Pharmacokinetic Study Evaluating Intravenous Ganaxolone Bolus in Healthy Adult Volunteers”

Date and time: Poster Session 1, October 19 from 4:15-5:15 p.m. CT

“Pharmacodynamic Effects of Intravenous Ganaxolone Bolus in Healthy Adult Volunteers”

Date and time: Poster Session 1, October 19 from 4:15-5:15 p.m. CT

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY^® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABA_A receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit www.marinuspharma.com.